Report from the Cardiovascular and Renal Drugs Advisory Committee: US Food and Drug Administration; June 15-16, 2005; Gaithersburg, Md

Circulation. 2005 Sep 27;112(13):2043-6. doi: 10.1161/CIRCULATIONAHA.105.573105.

Authors

Steven E Nissen¹; Cardiovascular and Renal Drugs Advisory Committee

Affiliation

¹ Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, OH 44195, USA. nissens@ccf.org

PMID: 16186439
DOI: 10.1161/CIRCULATIONAHA.105.573105

No abstract available

MeSH terms

Antihypertensive Agents / therapeutic use
Black People
Cardiovascular Agents / therapeutic use*
Drug Combinations
Drug Labeling
Epidemiologic Measurements
Heart Failure / drug therapy
Heart Failure / ethnology
Humans
Hydralazine / therapeutic use
Hypertension / drug therapy
Hypertension / physiopathology
Nitrates / therapeutic use
Pediatrics
Renal Agents / therapeutic use*
United States
United States Food and Drug Administration*

Substances

Antihypertensive Agents
Cardiovascular Agents
Drug Combinations
Nitrates
Renal Agents
Hydralazine